355 related articles for article (PubMed ID: 35046512)
1. Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease.
Nishizawa H; Maeda N; Shimomura I
Hypertens Res; 2022 Apr; 45(4):635-640. PubMed ID: 35046512
[TBL] [Abstract][Full Text] [Related]
2. Chronic kidney disease: Which role for xanthine oxidoreductase activity and products?
Polito L; Bortolotti M; Battelli MG; Bolognesi A
Pharmacol Res; 2022 Oct; 184():106407. PubMed ID: 35995347
[TBL] [Abstract][Full Text] [Related]
3. [URATE AS A POTENTIAL RISK FACTOR OF CARDIOVASCULAR AND RENAL DISEASES].
Butković M
Acta Med Croatica; 2016 Dec; 70(4-5):233-9. PubMed ID: 29087102
[TBL] [Abstract][Full Text] [Related]
4. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
Hisatome I; Li P; Miake J; Taufiq F; Mahati E; Maharani N; Utami SB; Kuwabara M; Bahrudin U; Ninomiya H
Circ J; 2021 Jan; 85(2):130-138. PubMed ID: 33342914
[TBL] [Abstract][Full Text] [Related]
5. Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease.
Waheed Y; Yang F; Sun D
Korean J Intern Med; 2021 Nov; 36(6):1281-1293. PubMed ID: 33045808
[TBL] [Abstract][Full Text] [Related]
6. Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function.
Jeon HJ; Oh J; Shin DH
PLoS One; 2019; 14(6):e0218510. PubMed ID: 31206563
[TBL] [Abstract][Full Text] [Related]
7. Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection.
Kielstein JT; Pontremoli R; Burnier M
Curr Hypertens Rep; 2020 Oct; 22(12):102. PubMed ID: 33128170
[TBL] [Abstract][Full Text] [Related]
8. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
Chen C; Lü JM; Yao Q
Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
[TBL] [Abstract][Full Text] [Related]
9. Serum uric acid and the risk of cardiovascular and renal disease.
Borghi C; Rosei EA; Bardin T; Dawson J; Dominiczak A; Kielstein JT; Manolis AJ; Perez-Ruiz F; Mancia G
J Hypertens; 2015 Sep; 33(9):1729-41; discussion 1741. PubMed ID: 26136207
[TBL] [Abstract][Full Text] [Related]
10. Xanthine oxidoreductase: A leading actor in cardiovascular disease drama.
Polito L; Bortolotti M; Battelli MG; Bolognesi A
Redox Biol; 2021 Nov; 48():102195. PubMed ID: 34844041
[TBL] [Abstract][Full Text] [Related]
11. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
Kuriyama S
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):1-5. PubMed ID: 31754883
[TBL] [Abstract][Full Text] [Related]
12. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.
Mallat SG; Al Kattar S; Tanios BY; Jurjus A
Curr Hypertens Rep; 2016 Oct; 18(10):74. PubMed ID: 27696189
[TBL] [Abstract][Full Text] [Related]
13. Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis.
Kimura Y; Tsukui D; Kono H
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830282
[TBL] [Abstract][Full Text] [Related]
14. The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors.
Liu N; Xu H; Sun Q; Yu X; Chen W; Wei H; Jiang J; Xu Y; Lu W
Oxid Med Cell Longev; 2021; 2021():1470380. PubMed ID: 33854690
[TBL] [Abstract][Full Text] [Related]
15. Uric Acid and Hypertension: a Review of Evidence and Future Perspectives for the Management of Cardiovascular Risk.
Borghi C; Agnoletti D; Cicero AFG; Lurbe E; Virdis A
Hypertension; 2022 Sep; 79(9):1927-1936. PubMed ID: 35658505
[TBL] [Abstract][Full Text] [Related]
16. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
Hu AM; Brown JN
Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
[TBL] [Abstract][Full Text] [Related]
17. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease.
Sampson AL; Singer RF; Walters GD
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009460. PubMed ID: 29084343
[TBL] [Abstract][Full Text] [Related]
18. Xanthine Oxidase and its Role as Target in Cardiovascular Disease: Cardiovascular Protection by Enzyme Inhibition?
Schuchardt M; Herrmann J; Tolle M; van der Giet M
Curr Pharm Des; 2017; 23(23):3391-3404. PubMed ID: 28413972
[TBL] [Abstract][Full Text] [Related]
19. [Hyperuricemia - more than gout : Impact on cardiovascular risk and renal insufficiency].
Sellin L; Kielstein JT; de Groot K
Z Rheumatol; 2015 May; 74(4):322-8. PubMed ID: 25962453
[TBL] [Abstract][Full Text] [Related]
20. Serum uric acid levels in kidney transplant recipients: A cause for concern? A review of recent literature.
Imasuen UJ; Swanson KJ; Parajuli S
Transplant Rev (Orlando); 2023 Jul; 37(3):100775. PubMed ID: 37437509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
